Financial Performance - Hua Medicine achieved a record revenue of RMB 492.9 million for the fiscal year 2025, representing a 93% increase compared to the same period in 2024, with cash receipts amounting to RMB 514.7 million[4]. - The pre-tax profit for fiscal year 2025 increased to RMB 1,106.4 million, primarily driven by the termination of the collaboration with Bayer and record sales of dorzagliatin[6]. - The commercialization business generated approximately RMB 114.9 million in profit for fiscal year 2025, a significant turnaround from a loss of RMB 28.5 million in 2024[6]. - The gross profit for the fiscal year ending December 31, 2025, was approximately RMB 280.4 million, an increase of about RMB 155.6 million or approximately 125% from the previous year[7]. - The total comprehensive income for the fiscal year ending December 31, 2025, increased by approximately RMB 1,356.9 million or about 543% to approximately RMB 1,106.8 million[7]. - The company reported a profit attributable to shareholders of RMB 1,106,353,000 for 2025, compared to a loss of RMB 250,144,000 in 2024, indicating a turnaround in financial performance[86]. Sales and Market Performance - Over 4 million boxes of dorzagliatin have been sold in China, benefiting over 500,000 patients through more than 3,000 hospitals and clinics since its launch in October 2022[5]. - Sales of Huadongning® reached approximately RMB 492.8 million for the year ending December 31, 2025, a 93% increase from RMB 255.9 million in the previous year, reflecting successful commercialization efforts[28]. - Revenue from major clients showed substantial growth, with Client A contributing RMB 162,469,000 in 2025, up from RMB 91,383,000 in 2024, representing an increase of 78%[73]. Research and Development - The company is advancing the second-generation GKA for obesity diabetes patients, with a multi-dose escalation study initiated in the U.S. and first patient enrollment expected by December 2025[5]. - The second-generation GKA has entered MAD studies in the U.S., with the first patient enrolled in December 2025, and top-line data expected by mid-2026[11]. - The company is focusing on internal research and business development to enhance glucose homeostasis and metabolic balance, targeting specific diseases such as frailty and mild cognitive impairment[5]. - The company plans to initiate clinical studies for Dorzagliatin in the treatment of frailty syndrome, which affects about 17% of Americans aged 50 and older[20]. Regulatory and Market Expansion - The National Healthcare Security Administration confirmed that the price of dorzagliatin will remain unchanged in the national medical insurance catalog for the calendar years 2026 and 2027[6]. - Hua Medicine received an additional five years of market exclusivity for dorzagliatin, extending the core patent protection until April 2034[6]. - The company has submitted regulatory applications for dorzagliatin in Hong Kong and Macau, with plans to launch in Hong Kong by mid-2026[10]. - Hua Medicine plans to officially launch dorzagliatin in Hong Kong under the brand name MYHOMSIS® in February 2026, following regulatory approval[5]. Financial Position and Cash Flow - As of December 31, 2025, the bank balance and cash position amounted to approximately RMB 1,092.3 million[7]. - Cash and cash equivalents amounted to RMB 1,092.3 million as of December 31, 2025[39]. - Cash used in operating activities was RMB 52.2 million for the year ending December 31, 2025, compared to RMB 418.0 million for the year ending December 31, 2024, indicating a significant improvement[41][43]. - The current ratio improved to 6.2 as of December 31, 2025, from 4.0 as of December 31, 2024, primarily due to a reduction in short-term loans[56][57]. Cost Management - The company incurred expenses of approximately RMB 433.4 million for the fiscal year ending December 31, 2025, with R&D expenses amounting to approximately RMB 145.3 million, a decrease of about RMB 69.8 million or approximately 32% from the previous year[7]. - Administrative expenses decreased from RMB 116.8 million for the year ending December 31, 2024, to RMB 114.5 million for the year ending December 31, 2025, primarily due to a reduction in rental costs[36]. - Research and development expenses decreased from RMB 215.1 million for the year ending December 31, 2024, to RMB 145.3 million for the year ending December 31, 2025, a reduction of RMB 69.8 million[35]. Employee and Corporate Governance - As of December 31, 2025, the group employed a total of 328 employees, an increase from 168 employees as of December 31, 2024[96]. - Employee costs for the year ended December 31, 2025, amounted to RMB 208.1 million, compared to RMB 157.2 million for the year ended December 31, 2024, reflecting a year-over-year increase of approximately 32.4%[96]. - The group’s board of directors confirmed compliance with the applicable standards of the corporate governance code throughout the year[100]. - The group plans to appoint a female director to its nomination committee by mid-2026, in line with revised corporate governance guidelines[100].

Financial Performance - The group's revenue increased from RMB 23.159 billion in 2024 to RMB 23.701 billion in 2025, representing a growth of approximately RMB 542 million or 2.34%[4] - The profit attributable to equity holders for the year ended December 31, 2025, was approximately RMB 4.037 billion, remaining relatively stable compared to RMB 4.043 billion in 2024[4] - Basic and diluted earnings per share for 2025 were RMB 0.8262, compared to RMB 0.8475 in 2024[4] - Total gross profit for the year was RMB 6.107 billion, down from RMB 6.254 billion in 2024[6] - Operating costs increased from RMB 16.905 billion in 2024 to RMB 17.594 billion in 2025[6] - The company reported a pre-tax profit of RMB 5.356 billion for 2025, compared to RMB 5.250 billion in 2024[6] - The total comprehensive income for the year was RMB 3.877 billion, down from RMB 4.840 billion in 2024[8] - The company recognized a net loss of RMB 449 million related to impairment losses on property, plant, and equipment in 2025[6] Dividends and Shareholder Returns - The board proposed a final dividend of RMB 0.38 per ordinary share for the year ended December 31, 2025[4] - The company proposed a final dividend of approximately RMB 2,076,784,000, equivalent to RMB 0.38 per share, subject to shareholder approval[44] - The board recommends a final dividend of RMB 0.38 per share, pending approval at the upcoming annual general meeting[129] Assets and Liabilities - Total assets reached RMB 92,078,580 million in 2025, up from RMB 81,812,423 million in 2024, indicating a growth of approximately 12.8% year-over-year[9] - Non-current liabilities decreased to RMB 26,672,650 million in 2025 from RMB 32,053,754 million in 2024, a reduction of about 16.5%[10] - Current liabilities increased to RMB 15,762,757 million in 2025, compared to RMB 10,252,808 million in 2024, representing a rise of approximately 54.5%[10] - Total equity rose to RMB 49,643,173 million in 2025 from RMB 39,505,861 million in 2024, marking an increase of about 25.6%[10] - The company’s total liabilities stood at RMB 42,435,407 million in 2025, slightly increasing from RMB 42,306,562 million in 2024[10] Cash Flow and Financing - The company’s cash and cash equivalents amounted to RMB 14,421,861 million in 2025, up from RMB 5,830,380 million in 2024, showing a growth of approximately 147.5%[9] - The net cash generated from operating activities was approximately RMB 7.39 billion, a decrease of 14.7% compared to RMB 8.67 billion as of December 31, 2024[90] - The total debt as of December 31, 2025, is approximately RMB 35,432,667,000, while cash and cash equivalents amount to RMB 14,421,861,000, reflecting an increase of 147% year-over-year[94] - The company has adjusted its capital structure by optimizing both equity and debt financing strategies to maintain a competitive cost of capital[93] Acquisitions and Investments - The company approved the acquisition of 100% equity in Shanghai Zhongyuan Liquefied Gas Transportation Co., Ltd. to unify the liquefied gas transportation business[16] - The total consideration for the acquisition of Shanghai Liquefied Gas is approximately RMB 598,290,000[17] - The company has approved the integration of Dalian Investment and COSCO Shipping (Shanghai) for the chemical logistics supply chain business on October 14, 2024[18] - The company acquired 100% equity of China COSCO Shipping Chemical Transportation Co., Ltd. and COSCO Shipping (Hong Kong) Co., Ltd.[18] - Dalian Haineng acquired 70% equity of Shenzhen Zhongyuan Longpeng Liquefied Gas Transportation Co., Ltd. and 87% equity of Hainan Zhaogang Shipping Co., Ltd. for a total consideration of approximately RMB 1,050,341,000[19] Operational Performance - The operating profit for the oil transportation segment was RMB 4,724,099,000 in 2025, compared to RMB 5,063,345,000 in 2024, indicating a decline of about 6.69%[31] - The LNG transportation segment reported an operating profit of RMB 1,256,186,000 in 2025, up from RMB 1,075,550,000 in 2024, reflecting an increase of approximately 16.79%[31] - The company reported a net profit attributable to joint ventures of RMB 487,563,000 in 2025, down from RMB 540,227,000 in 2024, a decrease of approximately 9.75%[31] - The domestic revenue for the year was RMB 5,741,985,000 in 2025, compared to RMB 6,101,998,000 in 2024, reflecting a decline of about 5.89%[36] - The international revenue increased to RMB 17,959,081,000 in 2025 from RMB 17,056,730,000 in 2024, representing a growth of approximately 5.29%[36] Market Outlook - The international oil transportation market is expected to see a significant increase in VLCC freight rates, with the average TCE for the TD3C route reaching approximately $57,500 per day, a 65% year-on-year increase[60] - China's crude oil imports are projected to reach 578 million tons in 2025, representing a 4.4% year-on-year increase, which is crucial for VLCC transportation demand[61] - The global oil supply is expected to grow by nearly 3.1 million barrels per day in 2025, with OPEC+ gradually increasing production[59] - The global LNG trade volume is expected to reach 431 million tons in 2025, a year-on-year increase of approximately 4.6%[65] Strategic Initiatives - The group aims to continuously extend its business from offshore energy transportation to energy chemical logistics supply chain[58] - The company is actively exploring synergies with its parent company, China Ocean Shipping Group, to enhance resource integration and value-added services[57] - The company is focusing on expanding its global business layout, particularly in high-value routes across the Pacific and Atlantic Oceans[78] - The company aims to enhance operational efficiency by diversifying its fleet deployment and customer structure, with a focus on key international oil companies[77] Corporate Governance - The company has established five specialized committees within the board of directors, including the Audit Committee, Remuneration and Assessment Committee, Nomination Committee, Strategic Committee, and Risk and Compliance Management Committee[140] - The Audit Committee consists of two independent non-executive directors and one non-executive director, responsible for reviewing financial reporting procedures and internal controls[141] - The board of directors is committed to enhancing shareholder value and maintaining independence and accountability through separate roles for the chairman and CEO[138] - The company has complied with the corporate governance code as per the listing rules during the reporting period[140] Employee and Pension Plans - As of December 31, 2025, the total number of employees in the group was 7,979, an increase from 7,854 on December 31, 2024[148] - Employee costs for the reporting period were approximately RMB 3.613 billion, compared to RMB 3.670 billion in 2024[148] - The company has contributed approximately RMB 50.64 million to its retirement benefit plan, which is 16% of the basic salaries of eligible employees for the reporting period[132] - The company established an employee pension plan in 2008, with total corporate contributions set at 8% of the previous year's total employee wages, and individual contributions at 2% of actual income[133]

Financial Performance - In 2025, the group's revenue decreased by 23.2% to HKD 316.0 million compared to 2024[9] - The group recorded a loss of HKD 4.8 million in 2025, primarily due to impairment of legacy IP licensing and digital collectibles platform assets[9] - Total revenue for the sports and leisure gaming business in 2025 is HKD 103.2 million, a decrease of 22.0% compared to 2024, primarily due to strategic adjustments to expand overseas markets[23] - The group recorded a gross profit of HKD 73.5 million for 2025, down from HKD 145.3 million in 2024[34] - Gross profit for 2025 was approximately HKD 73.5 million, a decrease of 49.4% compared to 2024, with a gross margin decline from 35.3% to 23.3%[36] - The annual loss for 2025 was HKD 4.78 million, compared to a loss of HKD 14.73 million in 2024, indicating an improvement in financial performance[65] - The company reported a loss attributable to owners of HKD 4,868,000 for 2025, compared to a loss of HKD 14,718,000 in 2024, showing an improvement in performance[86] User Engagement and Growth - The total user base of the group's platform, including overseas gaming users, increased by 22.5% to approximately 131.1 million by the end of 2025[5] - The average monthly active users on the platform grew by 10.5% year-on-year in 2025[5] - The group achieved over 600 million views for the "WBC Professional Boxing Championship," showcasing the integration of digital, sports, and entertainment[25] - The group successfully launched its AI analysis platform "Foretell," which has been approved for national-level integration in event analysis[6] - The group is focusing on key regions like Guangdong, Jiangsu, and Zhejiang to enhance market presence and operational efficiency, while optimizing store structures and eliminating underperforming outlets[21] - The core product "Football Superstar" showed strong global competitiveness, with daily active users exceeding 300,000 in Latin America and over 200,000 in Indonesia and Malaysia[37] AI Technology and Innovation - The group is focusing on AI technology development and application in response to the shift towards digital consumption patterns in China[6] - The company is set to launch its self-developed sports vertical AI analysis platform "Foretell" in January 2026, leveraging a 70 billion parameter language model and a 25-year global event database[12] - The company aims to deepen the application of AI in event operations, sports knowledge services, and interactive entertainment, focusing on data-driven new consumption and services[14] - The "Foretell" AI platform is set to complete its core technology development by 2025, integrating vertical domain large models and real-time data services for enhanced decision-making in sports betting[18] - The company emphasizes the integration of AI technology as a core driver for the entire industry chain, aiming to enhance its operational capabilities in event management and data development[14] Strategic Initiatives and Market Position - The group aims to enhance operational efficiency and asset structure while concentrating resources on high-growth segments[9] - The strategic position of the group is expected to benefit from rising consumer spending and the integration of AI in the sports industry[9] - The company has positioned itself as a key participant in the digital sports sector in the Hong Kong stock market, leveraging its extensive sports data accumulation and mature technology development capabilities[15] - The company is committed to building a leading international digital sports enterprise, focusing on core tracks and expanding into global markets[16] - The group plans to optimize its joint publishing business by focusing on higher-margin segments, reducing the number of low-return games, and collaborating with popular cultural IPs to attract a broader consumer base[24] Financial Management and Investments - The group has developed a focused investment strategy aimed at investing, acquiring, or forming alliances to enhance existing businesses and drive innovation[49] - The net cash generated from operating activities was HKD 66.8 million in 2025, compared to HKD 40.5 million in 2024[52] - The group has sufficient cash resources to meet its future working capital and other financing costs[53] - The company's total assets decreased to HKD 911,999,000 in 2025 from HKD 967,745,000 in 2024, reflecting a reduction in overall asset value[67] - The company’s equity attributable to owners increased to HKD 705,360,000 in 2025 from HKD 690,778,000 in 2024, indicating a positive trend in shareholder equity[68] Operational Challenges and Adjustments - The sports lottery retail business saw a revenue decline of 18.4% year-on-year in 2025, prompting a strategic review and optimization of operations[21] - The company recognized an impairment of goodwill amounting to HKD 48.4 million for its digital sports entertainment business in 2025[42] - Intangible asset write-offs amounted to approximately HKD 37.1 million in 2025, due to the inability to commercialize certain intellectual properties[43] - The company has not adopted any new or revised Hong Kong Financial Reporting Standards that would significantly impact its financial performance or position[70] - The company is currently evaluating the potential impact of newly issued or revised accounting standards, which are expected to have no significant effect on the consolidated financial statements[71] Future Outlook and Plans - The group aims to leverage the 2026 World Cup to maximize business synergies and value transformation across all business segments[32] - The esports ecosystem will be officially launched in 2026, focusing on creating a professional and international esports event system[31] - The company has set a performance guidance of 20% growth in EBITDA for the next fiscal year[121] - The board has approved a new marketing strategy focusing on digital channels, with a budget increase of 25% for the upcoming year[120] - The company plans to expand its market presence in Asia, targeting a 15% market share by the end of 2025[119]

Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 5,050,455 thousand, representing a 30% increase from RMB 3,884,694 thousand in 2024[17] - Gross profit for the same period was RMB 4,253,685 thousand, up from RMB 3,277,518 thousand in 2024, indicating a gross margin improvement[17] - Net profit for the year was RMB 1,205,440 thousand, a significant increase from RMB 881,329 thousand in 2024, reflecting a growth of approximately 37%[17] - The total assets of the company reached RMB 5,532,985 thousand, compared to RMB 4,473,469 thousand in 2024, marking a 24% increase[17] - The company's total liabilities decreased to RMB 863,061 thousand from RMB 969,946 thousand in 2024, indicating improved financial stability[17] - Earnings per share (EPS) for 2025 was RMB 2.46, compared to RMB 2.18 in 2024, showing an increase of about 13%[17] - The company declared a dividend of RMB 352,935 thousand for the year, compared to RMB 1,000,000 thousand in 2024, reflecting a strategic adjustment in capital allocation[17] - Return on equity (ROE) for 2025 was 29.5%, down from 34.9% in 2024, indicating a need for improved efficiency in generating profits from equity[17] Market Expansion and Strategy - Future strategies include a focus on product innovation and market expansion to sustain growth and enhance brand positioning in the beauty industry[18] - The company aims to enhance product development and channel construction to strengthen brand power and global recognition[24] - The company plans to enhance its offline sales network by increasing the number of brand stores in high-tier cities and penetrating higher-end malls[118] - Online expansion will focus on building its own official online store and broadening coverage on third-party e-commerce platforms, aiming to optimize online business[119] - The company aims to enhance global brand recognition and expand into overseas markets through dual-channel strategies of department store counters and online stores[124] Product Development and Innovation - The product portfolio expanded to 469 SKUs across makeup, skincare, and fragrance categories by December 31, 2025[22] - The company launched a high-end fragrance series "Guo Yun Ning Xiang" and "Wen Dao Dong Fang" in 2025, integrating cultural elements into product design[19] - The company launched a new high-end skincare series, "Liu Guang Fu Huo," which utilizes patented extracts from polar flowers to promote skin vitality[53] - The "Qi Yun Dong Fang" series, developed in collaboration with the Palace Museum, has received widespread acclaim for integrating traditional culture with modern aesthetics[43] - The company has developed over 70 new products and upgraded existing ones for the MAOGEPING brand in the fiscal year 2025, with 37 new cosmetic registrations added[81] Sales and Revenue Growth - Makeup product sales revenue reached RMB 2,996.3 million for the year ended December 31, 2025, representing a year-on-year growth of 30.0%[51] - The skincare product line generated revenue of RMB 1.873 billion for the year ending December 31, 2025, representing a year-on-year growth of 31.1%[61] - Online sales revenue surged by 38.8% from RMB 1,784.3 million in 2024 to RMB 2,477.1 million in 2025, with online direct sales increasing to RMB 1,944.6 million[131] - The company achieved the top position in domestic makeup sales during major shopping festivals on the Douyin platform, including the 3.8 Festival and Double 11[51] Corporate Social Responsibility - The company donated RMB 5 million to support victims of a fire incident and established a beauty education exchange center with a vocational college[23] - The company is committed to aligning the interests of shareholders, the company, and employees through the employee incentive plan, which does not involve the issuance of stock options or new shares[200] Employee and Management - The group has a total of 4,488 employees as of December 31, 2025, with 596 male employees and 3,892 female employees, reflecting a strong commitment to gender diversity[197] - The management team includes experienced professionals with backgrounds in finance and law, supporting the company's operational goals[190] - Specific training programs are offered based on departmental needs, including onboarding, business skills, and compliance training for new and existing employees[198] Marketing and Branding - The company emphasizes a content-driven branding strategy, including annual product launches and collaborations with cultural institutions, to enhance brand reputation[93] - The marketing campaign for Qixi Festival achieved over 100 million online exposures and won an outstanding marketing case award[108] - The New Year marketing campaign generated over 100 million exposures and led to the top sales of the Tmall color makeup set in its first week[110] Financial Management - The company reported a significant increase in revenue, achieving a total of $X million for the quarter, representing a Y% year-over-year growth[1] - The company has reported a strong cash position of $I million, providing flexibility for future investments and growth initiatives[9] - The net cash inflow from operating activities increased from RMB 968.6 million in 2024 to RMB 1,199.4 million in 2025, primarily due to increased cash inflows from sales growth[153]

Financial Performance - The group's revenue for the fiscal year ending December 31, 2025, was approximately HKD 3,190.9 million, a decrease of about 40.0% compared to HKD 5,322.5 million in the fiscal year 2024[2]. - The international express and parcel business recorded a loss of HKD 43.4 million in fiscal year 2025, compared to a profit of approximately HKD 0.2 million in fiscal year 2024[2]. - The air freight business incurred a loss of HKD 79.0 million in fiscal year 2025, down from a profit of approximately HKD 34.2 million in fiscal year 2024[2]. - The sea freight business's segment performance decreased by approximately 24.4% to about HKD 25.6 million in fiscal year 2025, compared to HKD 33.9 million in fiscal year 2024[2]. - The group recorded a loss attributable to equity shareholders of approximately HKD 145.6 million in fiscal year 2025, compared to a loss of about HKD 40.8 million in fiscal year 2024[2]. - The total comprehensive income for the year was a loss of HKD 147.8 million, compared to a loss of HKD 53.7 million in the previous year[4]. - The total loss before tax for 2025 was HKD 153,303, compared to a loss of HKD 37,920 in 2024[9]. - The group reported a basic and diluted loss per share of HKD 34.84 for fiscal year 2025, compared to HKD 9.75 for fiscal year 2024[3]. - The company reported a basic and diluted loss per share of HKD 0.348 in 2025, compared to HKD 0.097 in 2024[14]. Assets and Liabilities - The group's total assets less current liabilities amounted to HKD 1,128.7 million, down from HKD 1,254.2 million in fiscal year 2024[6]. - The group's cash and cash equivalents were HKD 608.2 million, a decrease from HKD 672.2 million in fiscal year 2024[5]. - Trade receivables at the end of the reporting period amounted to HKD 801,056, an increase from HKD 734,159 in 2024[18]. - Trade payables at the end of the reporting period were HKD 309,249, up from HKD 265,884 in 2024[19]. - As of December 31, 2025, the group's operating capital was approximately HKD 888.5 million, a decrease of about 22.7% from HKD 1,149.5 million on December 31, 2024[38]. - The current ratio decreased from approximately 3.25 times on December 31, 2024, to about 2.27 times on December 31, 2025[38]. - The group's bank balance and cash amounted to approximately HKD 608.2 million, down about 9.5% from HKD 672.2 million on December 31, 2024[38]. - The group reported an operating cash inflow of approximately HKD 16.3 million for the fiscal year 2025, compared to an outflow of approximately HKD 72.8 million in the fiscal year 2024[38]. - The group has no outstanding bank loans as of December 31, 2025, consistent with the previous year[38]. Dividends - The board resolved not to declare a final dividend for the fiscal year 2025, consistent with the previous fiscal year[2]. - The company did not recommend any final dividends for the fiscal years 2025 and 2024[17]. - The board does not recommend the distribution of a final dividend for the fiscal year 2025, consistent with the previous fiscal year[58]. Revenue Breakdown - Total revenue for the air freight segment in 2025 was HKD 1,970,320, a decrease of 39.7% from HKD 3,272,682 in 2024[9]. - International express and parcel services generated revenue of approximately HKD 565,959 in 2025, down 45.5% year-over-year, with a total of 26.3 million parcels delivered, a decline of 49.0%[20]. - The gross profit for international express and parcel services was HKD 6,300, a decrease of 74.6% compared to the previous year[20]. - The air freight agency business generated approximately HKD 1,970.3 million in revenue, accounting for 61.7% of total revenue, with a year-on-year decline of 39.8%[25]. - The sea freight agency business achieved revenue of approximately HKD 492.9 million, representing 15.4% of total revenue, with a year-on-year decrease of 41.0%[26]. - In the fiscal year 2025, the international supply chain business generated revenue of approximately HKD 69.9 million, accounting for 2.2% of the total revenue, representing a year-on-year decline of 13.8%[28]. Operational Strategies - The company aims to strengthen its international network by improving trunk transportation, collection, distribution, and last-mile delivery capabilities, enhancing the coverage and efficiency of its cross-border logistics network[21]. - The company is advancing its digital transformation in international freight by integrating AI and big data technologies to enhance operational efficiency and service quality[25]. - The company is focusing on cost control and operational efficiency improvements through the adoption of advanced automation equipment and productivity data reporting[22]. - The company is enhancing its market capabilities by developing a comprehensive product matrix to meet diverse customer needs and improving service levels[23]. - The group aims to enhance its global network by prioritizing the "1+7" key country and region network construction, focusing on asset investment and strategic cooperation[47]. - The group plans to optimize its product service system by providing differentiated solutions tailored to various customer needs, transitioning from single transportation services to comprehensive supply chain services[48]. - The group will continue to strengthen its digital transformation in customer service and customs systems to improve efficiency and processing capabilities[36]. - The group will enhance and upgrade relevant products and services, promoting multi-product collaboration such as "express + freight" and "shipping + warehousing" to enrich the standardized product system for overseas warehousing and distribution[49]. - The group aims to strengthen cross-border trunk transportation capabilities and enhance the safety and flexibility of the cross-border transportation network, focusing on major routes in Europe, North America, and Asia[50]. - The group will deepen the application of emerging technologies such as artificial intelligence and big data to improve operational efficiency and service quality, reducing reliance on external systems[51]. - The group plans to optimize its organizational structure and talent team to support the rapid development of international business, enhancing operational efficiency and resource allocation[52]. - The group will strengthen the synergy between domestic and international operations, leveraging the advantages of its domestic network to enhance global logistics stability and controllability[54]. - The group will promote the integration of domestic operational management experience into international business, enhancing quality management and cost control[54]. Workforce and Governance - The company incurred employee costs totaling HKD 261,286 in 2025, slightly down from HKD 264,265 in 2024[13]. - The group has approximately 1,140 employees as of December 31, 2025, with employee expenses around HKD 261.29 million for the fiscal year 2025[55]. - The company has adopted the corporate governance code as per the listing rules, confirming compliance for the fiscal year 2025[61]. - The board of directors has adhered to the standards for securities trading as outlined in the listing rules for the fiscal year 2025[62]. - An audit committee has been established, consisting of one non-executive director and two independent non-executive directors, to review the audited financial performance for the fiscal year 2025[63]. Future Outlook - In 2025, China's cross-border e-commerce is expected to achieve an import and export value of RMB 21.9 trillion, representing a year-on-year growth of nearly 11%[21]. - The International Monetary Fund forecasts global economic growth rates of 3.3% and 3.2% for 2026 and 2027, respectively[45]. - China's total goods trade import and export volume exceeded RMB 45 trillion in 2025, a year-on-year increase of 3.8%, with exports at RMB 27 trillion (up 6.1%) and imports at RMB 18.5 trillion (up 0.5%)[46]. - The company established a partnership with Xiaomi Group in 2025 to provide customized logistics and warehousing solutions, enhancing supply chain stability for high-value and fragile goods[29]. - The company improved its supply chain management system, significantly reducing abnormal rates, damage rates, and delay rates, thereby enhancing operational quality[30]. - The global hub layout is centered around a "1+7" strategy, with ongoing development of logistics networks in key regions including Central Asia, the Middle East, and North America[31]. - The company is integrating emerging technologies such as AI and big models into its operations, enhancing efficiency and decision-making through a unified data system[35]. - The final results announcement and annual report for the fiscal year 2025 will be published on the Hong Kong Stock Exchange and the company's website at the appropriate time[64]. - The chairman expressed gratitude to colleagues, shareholders, clients, banks, and business partners for their trust and support[65]. - The board includes two executive directors, four non-executive directors, and three independent non-executive directors as of the announcement date[67].

Financial Performance - Revenue for the six months ended December 31, 2025, increased to HK$33,524,000, representing a 55% growth compared to HK$21,662,000 in the previous period[8]. - Gross profit rose to HK$2,068,000, up 44% from HK$1,433,000 in the previous period[8]. - Loss for the period was HK$31,145,000, compared to a loss of HK$24,999,000 in the previous period, indicating a 25% increase in losses[8]. - Total comprehensive expense for the period was HK$31,441,000, compared to HK$30,061,000 in the previous period, reflecting a slight increase of 4.6%[9]. - For the six months ended December 31, 2025, the company reported a loss before tax of HK$31,121,000, compared to a loss of HK$24,998,000 for the same period in 2024, indicating a deterioration in financial performance[21]. - The total comprehensive expense for the period was HK$31,441,000, which includes a loss of HK$27,836,000 and an exchange difference of HK$281,000[21]. - The loss per share for the period was HK$(2.83) cents, compared to HK$(2.67) cents in the previous period[10]. - For the six months ended December 31, 2025, the loss attributable to owners of the Company was HK$27,836,000, compared to HK$21,607,000 for the same period in 2024, representing a 28.6% increase in loss[58]. - The basic loss per share for the period was HK$2.83, compared to HK$2.67 for the previous year, indicating a 6% increase in loss per share[58]. Assets and Liabilities - Non-current assets decreased to HK$44,520,000 from HK$45,629,000, a decline of 2.4%[12]. - Current liabilities increased to HK$209,019,000 from HK$181,616,000, marking a 15% rise[12]. - Net assets decreased to HK$77,839,000 from HK$109,280,000, a reduction of 29%[14]. - Cash and cash equivalents dropped to HK$5,188,000 from HK$11,920,000, a decrease of 56%[12]. - As of December 31, 2025, cash and cash equivalents decreased to HK$5,188,000 from HK$7,202,000 at the end of 2024, reflecting a decline in liquidity[24]. - The carrying value of property, plant, and equipment as of December 31, 2025, was HK$10,700,000, down from HK$11,813,000 as of July 1, 2025, indicating a decrease of 9.4%[65]. - The total inventories as of December 31, 2025, amounted to HK$6,524,000, a decrease from HK$6,894,000 as of June 30, 2025, representing a 5.4% decline[71]. - As of December 31, 2025, trade receivables amounted to HK$193,184,000, an increase from HK$162,661,000 as of June 30, 2025[73]. - The provision for impairment losses on trade receivables increased to HK$72,533,000 from HK$47,135,000, indicating a rise in expected credit losses[73]. - Loan receivables, net of expected credit losses, decreased to HK$44,646,000 from HK$48,978,000, with 15 borrowers involved[78]. Revenue Breakdown - Revenue from Smart City Solutions decreased to HK$11,931,000 in 2025 from HK$15,833,000 in 2024, a decline of about 24.1%[41]. - Revenue from the design and sales of renewable energy products and solutions increased significantly to HK$21,593,000 in 2025 from HK$5,829,000 in 2024, marking an increase of approximately 270.5%[41]. - The Group's total revenue recognized at a point in time was HK$33,299,000, with an additional HK$225,000 recognized over time[44]. - The Group reported total revenue of approximately HK$33.5 million for the six months ended December 31, 2025, representing an increase of approximately 54.4% compared to HK$21.7 million in the previous period, mainly due to the successful completion of substantial solar photovoltaic system projects[117][122]. Expenses and Costs - General and administrative expenses decreased to HK$15,802,000 from HK$17,555,000, a reduction of 10%[8]. - Cash used in operating activities amounted to HK$21,645,000, an increase from HK$15,857,000 in the previous year, reflecting higher operational costs[21]. - The total depreciation expense for property, plant, and equipment was HK$1,177,000, up from HK$840,000 in the prior year, reflecting a 40% increase[51]. - Finance costs increased to approximately HK$288,000 from approximately HK$89,000 in the previous period, mainly due to interest incurred from bank borrowings and promissory notes[127][130]. Investments and Financial Assets - The Group's investment activities in Hong Kong listed securities resulted in a fair value gain of approximately HK$1.9 million during the period, attributed to improved market sentiment[164]. - As of December 31, 2025, the fair value of listed equity investments in Hong Kong was approximately HK$39.2 million, an increase from HK$36.5 million as of June 30, 2025[165]. - The Group recorded a financial asset gain of approximately HK$1.9 million during the review period, attributed to a recovery in the Hong Kong stock market in the second half of 2025[166]. - The Group's investment portfolio included 8 equity securities listed on the Stock Exchange of Hong Kong, with 6 on the Main Board and 2 on the GEM[165]. - The accumulated unrealized loss for the investment in Zijing International Financial Holdings Limited was HK$12,509,411 as of December 31, 2025[171]. Business Operations and Strategy - The Group's business model focuses on delivering comprehensive technology solutions, integrating hardware and software into tailored packages, with a strategic focus on Green Energy Initiative, Smart City Solutions, and Renewable Energy sectors[128][131]. - The Renewable Energy Business has faced challenges due to delays in approvals and a reduction in Feed-in Tariff (FiT) rates, impacting customer orders[144][145]. - The Group has completed five major self-funded SPV projects in Hong Kong, with a total contract value of approximately HK$21 million[148]. - The SPV Business is now a core component of the Renewable Energy Business, with ongoing negotiations in Southeast Asia[147]. - The Group is focusing on building long-term relationships with financially stable customers, primarily government-owned entities, to minimize default risk[136][139]. - The data center business in China has experienced stagnation due to semiconductor shortages and geopolitical sanctions, leading to a strategic reduction in operations[140][141]. - The Group has proactively engaged customers to promote SPV system installations for self-use post-FiT scheme expiration, enhancing technical and economic viability[145]. - The Group's suppliers have provided extended credit periods, recognizing the low credit risk associated with government-owned customers[137]. - The Group's smart city solution business includes sales of smart construction solutions, IoT solutions, and IDC business, reflecting a comprehensive approach to technology integration[134]. Share Capital and Management - The authorized share capital remained at HK$1,600,000,000 as of December 31, 2025, with issued and fully paid share capital at HK$3,397,446,000[103]. - Key management personnel remuneration for the six months ended December 31, 2025, was HK$3,326,000, slightly down from HK$3,366,000 in the same period of 2024[105].

Financial Performance - Total revenue for the year ended December 31, 2025, reached RMB 1,006,934,000, representing a year-on-year increase of 7.0% compared to RMB 941,414,000 in 2024[4] - Gross profit for the same period was RMB 551,246,000, with a gross margin of 54.7%, up 0.5 percentage points from 54.2% in 2024[4] - Adjusted net profit for the year was RMB 140,218,000, a decrease of 7.4% from RMB 151,369,000 in 2024, with an adjusted net profit margin of 13.9%[4] - Operating profit decreased from RMB 168.2 million in 2024 to RMB 139.8 million in 2025, a decline of 16.9%[49] - The net profit for the year turned positive at RMB 140.2 million in 2025, compared to a loss of RMB 481.5 million in 2024, marking a turnaround of 129.1%[49] - Basic and diluted earnings per share for the year ended December 31, 2025, were RMB 3.81, compared to a loss of RMB 8.62 in 2024[84] - The company reported a pre-tax profit of RMB 135,484,000 for 2025, a significant recovery from a loss of RMB 488,675,000 in 2024[102] Revenue Breakdown - Revenue from enterprise solutions grew by 7.3%, from RMB 932.5 million in 2024 to RMB 1,000.2 million in 2025[51] - Revenue from the automotive and transportation sector surged by 21.9%, increasing from RMB 198.7 million in 2024 to RMB 242.2 million in 2025[54] - Revenue from the financial sector increased by 2.3%, from RMB 100.7 million in 2024 to RMB 102.9 million in 2025[54] - The geographical revenue breakdown shows that revenue from mainland China was RMB 979,008,000 in 2025, an increase from RMB 897,430,000 in 2024, representing a growth of 9.1%[97] Project and Contract Updates - The number of ongoing projects at the beginning of the year increased by 50.7% to 226, while the number of new projects awarded rose by 11.9% to 422[6] - The year-end backlog of unfulfilled contracts increased by 57.4% to RMB 1,048,853,000, compared to RMB 666,231,000 in 2024[7] - The company has won a contract for the "Smart Port" project at Ezhou Huahu Airport, expanding its application in air transport and logistics[25] - The company secured a contract worth nearly RMB 300 million for the "AI + Elderly Care" project in Neijiang, marking a significant milestone in its health sector initiatives[28] Research and Development - Research and development expenses rose significantly by 67.7%, from RMB 133.7 million in 2024 to RMB 224.3 million in 2025[49] - The company aims to enhance its R&D team with a budget allocation of RMB 159.8 million, with RMB 97.0 million utilized as of December 31, 2024[118] - The company has developed several AI models for health monitoring, including a health warning AI model that predicts chronic disease risks and a cognitive ability assessment model for early screening[31] - The company completed over ten core product iterations and upgrades during the reporting period, including intelligent classification and knowledge base systems, improving standardization and replicability of governance services[17] Operational Efficiency and Technology - The company aims to leverage its interactive AI technology to enhance operational efficiency and drive digital transformation across various industries[9] - The new generation of intelligent agents integrates large language model capabilities to address common challenges in enterprise-level deployment, enhancing reliability and adaptability[10] - The company has developed a trusted intelligent agent technology architecture that supports complex business scenarios through multi-modal perception and multi-agent collaboration[11] - The intelligent knowledge base has upgraded knowledge acquisition from keyword search to semantic understanding, enhancing efficiency and consistency in frontline service responses[19] Financial Position and Liabilities - As of December 31, 2025, total liabilities amounted to RMB 1,253.4 million, up from RMB 794.6 million as of December 31, 2024[75] - The debt-to-asset ratio as of December 31, 2025, was 42.2%[77] - The total liabilities increased to RMB 1,245,766,000 in 2025, up from RMB 781,210,000 in 2024, reflecting a growth of 59.3%[86] Cash Flow and Investments - Cash generated from operating activities was RMB 212.5 million in 2025, significantly improving from a cash outflow of RMB 129.2 million in 2024[72] - Cash used in investing activities amounted to RMB 540.5 million in 2025, primarily for the acquisition of property, equipment, and intangible assets totaling RMB 498.9 million[73] - The net cash generated from financing activities during the reporting period was RMB 249.1 million, primarily from bank loans[74] Corporate Governance and Compliance - The company expresses gratitude to shareholders, management, employees, business partners, and customers for their ongoing support and contributions[132] - The audit committee consists of three members, including Mr. Liang Jiankang, who possesses the appropriate professional qualifications as per the Listing Rules[128] - The financial statements are prepared in accordance with applicable accounting standards, reflecting the group's financial status accurately[128] - The company is committed to adhering to the corporate governance code as stipulated in the Listing Rules[133]

Financial Performance - Keymed Biosciences Inc. reported a revenue of RMB 716.3 million for the year ending December 31, 2025, representing a 67% increase compared to RMB 428.1 million in 2024[2]. - The cost of sales surged to RMB 88.0 million, a 622% increase from RMB 12.2 million in the previous year[2]. - The company achieved a gross profit of RMB 628.3 million, up 51% from RMB 415.9 million in 2024[2]. - The net loss for the year was RMB 522.6 million, a marginal increase of 1% from RMB 514.9 million in 2024[2]. - The company's revenue for 2025 reached RMB 716.313 million, a significant increase from RMB 428.124 million in 2024, representing a growth of approximately 67.5%[67]. - Gross profit for 2025 was RMB 628.265 million, compared to RMB 415.924 million in 2024, reflecting a gross margin improvement[67]. - The company incurred a loss before tax of RMB 520,723 thousand, compared to a loss of RMB 508,647 thousand in 2024, reflecting ongoing investment in growth[104]. - The total comprehensive loss for the year was RMB 510,251 thousand, slightly improved from RMB 513,521 thousand in the previous year[105]. Research and Development - Research and development expenses slightly decreased by 2% to RMB 723.5 million from RMB 735.2 million in 2024[2]. - The company has established a comprehensive integrated platform for drug development, covering all key functions from target validation to clinical development and production[23]. - The company is continuously recruiting talent to meet the growing demands of product commercialization, R&D, clinical, production, and operations[22]. - The company has entered into multiple licensing agreements for drug development, indicating a strategic focus on expanding its product pipeline and market presence[120][122][123]. - Research and development expenditures increased by 10% to support ongoing projects and new drug applications[144]. Product Pipeline and Clinical Trials - Keymed is advancing multiple clinical trials for its pipeline products, including CMG901/AZD0901 and CM512, with significant milestones achieved in 2025[5][7]. - CM336 achieved an objective response rate (ORR) of 95.2% and a complete response (CR) rate of 76.2% in a Phase II clinical study for relapsed or refractory multiple myeloma (RRMM) patients[11]. - CM336 received Fast Track Designation from the FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) on January 23, 2026[13]. - CM313 completed a Phase II clinical study evaluating its safety and efficacy in patients with primary immune thrombocytopenia[15]. - CM383 is undergoing a Phase Ib clinical study for safety and tolerability in patients with mild cognitive impairment and mild Alzheimer's disease, with patient enrollment completed by December 2025[16]. - CM350 is in the dose escalation phase of an I/II clinical study for advanced solid tumors[18]. - CM326 is advancing multiple Phase III clinical trials for various indications, including moderate to severe asthma and chronic rhinosinusitis with nasal polyps[19]. - CM355 demonstrated an overall response rate (ORR) of 82% and a complete response (CR) rate of 59% in patients with relapsed/refractory B-cell non-Hodgkin lymphoma[20]. - CM369 is in an ongoing Phase I dose escalation trial for advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma[21]. Financial Position and Assets - As of December 31, 2025, total assets were RMB 4.218 billion, up from RMB 3.767 billion in 2024, showing a growth of approximately 12%[75]. - The company's total liabilities as of December 31, 2025, were RMB 1.443 billion, compared to RMB 1.291 billion in 2024, reflecting an increase in financial obligations[75]. - The net cash flow from operating activities for 2025 was RMB 712 million, a decrease from RMB 790 million in 2024, indicating tighter cash management[76]. - The debt-to-asset ratio remained stable at 34% as of December 31, 2025, consistent with the previous year[79]. - Non-current assets totaled RMB 1,794,691,000 in 2025, up 38.0% from RMB 1,300,540,000 in 2024[106]. - Current assets decreased slightly to RMB 2,422,842,000 in 2025 from RMB 2,466,026,000 in 2024, a decline of 1.8%[106]. - The company's net asset value increased to RMB 2,774,923,000 in 2025, reflecting a growth of 12.1% from RMB 2,475,212,000 in 2024[107]. Strategic Partnerships and Agreements - Ouro Medicines signed a merger agreement with Gilead Sciences for a total transaction value of up to $2.175 billion, including an initial payment of $1.675 billion and up to $500 million in milestone payments[14]. - The company has established partnerships for the development and commercialization of candidate drugs through joint ventures and licensing arrangements[24]. - The company entered into a licensing agreement with Timberlyne Therapeutics, receiving an upfront payment of USD 25,000,000 (approximately RMB 179,233,000) in 2025[119]. - The company has established partnerships with three leading research institutions to accelerate drug development timelines[144]. Market and Growth Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 20% and an EBITDA margin improvement of 5%[144]. - New product launches are expected to contribute an additional $50 million in revenue, with a focus on innovative biopharmaceuticals[142]. - The company is expanding its market presence in the Asia-Pacific region, targeting a 30% increase in market share by 2026[143]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach, with a budget of $100 million allocated for potential deals[142]. Employee and Operational Insights - As of December 31, 2025, the company has 1,625 full-time employees, with over 407 in the commercialization team and nearly 432 in drug discovery and clinical operations[22]. - The company has established three pilot production lines and three commercial production lines, with a total capacity of 21,800 liters; an additional stainless steel production line with a capacity of 24,000 liters has been installed and is about to be put into use[22]. - The company plans to expand its cGMP-compliant production capacity to meet the anticipated increase in demand for candidate drugs[66]. Shareholder and Governance - The board resolved not to recommend the payment of a final dividend for the year ended December 31, 2025[90]. - The annual general meeting of shareholders is scheduled for June 26, 2026[91]. - The company has established an audit committee to oversee financial reporting processes and ensure compliance with applicable accounting standards[97]. - The board has approved a share buyback program worth $20 million to enhance shareholder value[142].

青島銀行股份有限公司（「本行」或「青島銀行」）董事會（「董事會」）欣然宣佈本行及其附屬 公司（「本公司」）截至2025年12月31日止年度（「報告期」）根據國際會計準則委員會頒佈 的《國際財務報告會計準則》（「國際財務報告會計準則」）編製的經審計年度業績（「年度業 績」）。董事會及其下轄的審計委員會已審閱並確認此年度業績。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Bank of Qingdao Co., Ltd.* 青 島 銀 行 股 份 有 限 公 司 * （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （H股股份代號：3866） 截至2025年12月31日止年度業績 除特別說明外，本業績公告所述的金額幣種為人民幣，本業績公告所載財務數據為本公 司合併口徑數據。 第一節 公司基本情況 1.1 公司基本情況 | 法定中文名稱： | 青島銀行股份有限公司（簡稱：青島銀行） | | | | --- | --- ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「香港聯交所」）對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 中國國際海運集裝箱（集團）股份有限公司 CHINA INTERNATIONAL MARINE CONTAINERS (GROUP) CO., LTD. （於中華人民共和國註冊成立之股份有限公司） （H股股份代號：02039） （A股股份代號：000039） 二零二五年度業績公告（年度報告摘要） 1 重要提示 1.1 中國國際海運集裝箱（集團）股份有限公司（「本公司」或「公司」，與其附屬公司合稱 「本集團」或「中集」）董事會（「董事會」）及董事（「董事」）、高級管理人員除副總裁于 玉群先生因突發個人身體原因無法簽署關於2025年年報的書面確認意見之外， 其他董事、高級管理人員均保證二零二五年度業績公告（「本公告」）所載數據不存 在虛假記載、誤導性陳述或者重大遺漏，並對該截至2025年12月31日止之年度報 告（「2025年年度報告」）之摘要內容的真實性、準確性和完整性承擔個別及連帶責 任 ...